Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.51 USD

74.51
2,526,652

+1.21 (1.65%)

Updated Jul 18, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Exercises Options to Three Arcus Programs

by Zacks Equity Research

Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).

Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)

by Zacks Equity Research

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data

by Zacks Equity Research

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb

by Zacks Equity Research

Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q3 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.

Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales

by Zacks Equity Research

Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.

Mark Vickery headshot

Markets Close at or Near Record Highs; Sales Misses for AAPL, AMZN, SBUX

by Mark Vickery

Most of these economic metrics and earnings reports are a peek in the rearview mirror; the real news is ahead of us.

Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 54.07% and 19.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?

by Zacks Equity Research

Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

by Sweta Killa

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More

by Zacks Equity Research

Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Why Gilead (GILD) Might Surprise This Earnings Season

by Zacks Equity Research

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $67.24, moving +0.37% from the previous trading session.

What is in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More

by Zacks Equity Research

Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients

by Zacks Equity Research

Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.